The vascular endothelium maintains a relatively vasodilated state via the release of nitric oxide (NO), a process that could be disrupted by hyperhomocysteinaemia. Since endothelial dysfunction is associated with increased systemic vascular resistance that is the hallmark of sustained arterial hypertension, we hypothesised that in patients with both hypertension and coeliac disease with hyperhomocysteinaemia (via malabsorption of essential cofactors), treatment of the latter disease could improve blood pressure (BP) control. A single patient with proven sustained hypertension and newly-diagnosed coeliac disease had baseline and post-treatment BP and endothelial function assessed by ambulatory BP monitoring (ABPM) and brachial artery forearm occlusion plethysmography respectively. This 49 year-old woman had uncomplicated sustained hypertension proven on repeated ABPM carried out 6 weeks apart (daytime mean 151/92 mm Hg and 155/95 mm Hg), and sub-clinical coeliac disease (gluten-sensitive enteropathy). Initial assessments
Introduction
The serendipitous observation of Furchgott and Zawadzki 1 in 1980 that an intact endothelium is essential for a normal vasodilatory response to acetylcholine (ACh) has revolutionised vascular biology. This led to the discovery that the vascular endothelium releases nitric oxide (NO) continuously to regulate the vascular tone favouring a vasodilated state. Loss of this NO-driven vasodilatory control or 'endothelial dysfunction' hence causes vasoconstriction that increases the vascular resistance. Hypertension is one common vascular disease that is primarily due to an unexplained rise in systemic vascular resistance, and it is also associated with endothelial dysfunction. At present, there is controversy whether endothelial dysfunction in hypertension initiates the disease process, or it is Journal of Human Hypertension simply an epiphenomenon. Interestingly, normotensive offsprings of hypertensive parents who are more at risk of developing hypertension in the future have been reported to have impaired endothelial function. 2, 3 This finding would support the notion that endothelial dysfunction precedes hypertension, although there are as yet no direct longitudinal follow-up data to show that normotensive young individuals with worse endothelial dysfunction are more likely to develop hypertension over time. More recently, vitamin C, a potent antioxidant which reduces endothelial dysfunction has been reported to lower blood pressure (BP) significantly in hypertensives 4 suggesting that to some extent, endothelial dysfunction maintains hypertension. At least in rats, endothelial dysfunction produced experimentally initiates the hypertensive disease process. 5, 6 The vascular endothelium is exceedingly sensitive to risk factors for vascular diseases such as smoking, 7 hypercholestrolaemia, 8 hyperglycaemia 9 and hyperhomocysteinaemia. 10 These factors which cause endothelial dysfunction through diverse mechanisms are also commonly found clustered within many hypertensive individuals. 11 Thus, the primacy of endothelial dysfunction in causing hypertension in human potentially can be elucidated by finding a disease model whereby BP is lowered by reversing endothelial dysfunction. Here we report an extended case study of a patient confirmed to have mild and uncomplicated hypertension who was incidentally diagnosed to have sub-clinical coeliac disease. Coeliac disease is a readily reversible malabsorption syndrome that is associated with relative folate and vitamin B 12 deficiency. These are essential cofactors needed for homocysteine metabolism, the lack of which cause an elevation in homocysteine level that in turn impairs the vascular endothelial function. It has been shown that even borderline high homocysteine levels are associated with vascular diseases.
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Methods
Patient
A 49-year old woman who was a sedentary life-long non-smoker with 1-year history of hypertension was referred for assessment in our specialist hypertension clinic. She was incidentally found to have untreated coeliac disease. She was asymptomatic other than a long-standing vague feeling of fatigue. She had previous back surgery, right kidney pyloroplasty for ureteric obstruction and had two unevenful pregnancies, but one of her daughters has spina bifida occulta. Fully informed written consent was obtained from this patient prior to her taking part in this unique observational study, which involved brachial artery endothelial function assessment (see below), a technique that we have considerable experience in and had been approved for use in hypertensives in our department by the Tayside medical ethics committee.
Blood pressure measurements
BP was measured in triplicate by trained hypertension research nurses using a standard mercury sphygmomanometer at 1-min intervals after a seated rest of 2 min. The mean of these three readings was used to define clinic BP. Ambulatory BP monitoring (ABPM) (Spacelabs 90207, Redmond, WA, USA) was done on an active day. The device was programmed to measure BP every 15 min during daytime from 08.00 to 22.00. The following spurious readings were discarded by editing software; systolic BP Ͻ diastolic BP, diastolic BP Ͼ 160 or Ͻ 40 mm Hg and systolic BP Ͼ 260 mm Hg or Ͻ 50 mm Hg. Normotension was defined as a daytime mean ABPM of Ͻ135/85 mm Hg.
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Brachial artery endothelial function assessment
The vascular endothelial function was assessed using differential forearm venous occlusion plethysmography by CAJF/NT who were blinded to other measurements in a temperature-controlled room (24 ± 0.5°C). The methodology of this technique has previously been described elsewhere. 14 The forearm blood flow measurements (mL/100 mL/min) were performed after each of the three 5-min incremental dosages of the following agents infused intraarterially into the non-dominant brachial artery: acetylcholine (ACh, 25, 50, and 100 nmol/min), sodium nitroprusside (SNP, 4.2, 12.6, and 37.8 pmol/min) and n-monomethyl-L-arginine (L-NMMA, 1, 2, and 4 mol/min). The responses to these agents were expressed as the percentage difference in forearm blood flows between the infused and control arms (⌬FBF) whilst ensuring that the baseline blood flows were the same in both arms at the beginning of each infusion. Each infusate tested different aspects of the vascular function, ACh, endothelium-dependant vasodilatation or stimulated NO release, SNP, endothelium-independant vasodilatation and L-NNMA, endothelium-dependant vasoconstriction or basal nitric oxide production respectively.
Results
Our patient was of slim build, and had a normal body mass index of 22 kg m total homocysteine levels were 16 mol/L (Ͻ15, fasting), 25 (2 h) and 31 (4 h) following a 6-g methionine load. Echocardiography detected no cardiac hypertrophy. Anti-endomesial antibody was positive and a distal duodenal biopsy showed sub-total villous atrophy consistent with the diagnosis of coeliac disease. Brachial artery vascular endothelial function was assessed using forearm differential occlusion plethysmography (Figure 2 ).
Since coeliac disease is a form gluten-sensitive enteropathy, standard gluten-free dietary advice was offered following the baseline investigations. She was also treated with oral ferrous sulphate 200 mg three times daily, folate 5 mg daily and B 6 50 mg daily for 3 months, and weekly intramuscular injection of vitamin B 12 1000 g for the first 4 weeks followed by monthly injection for the next 2 months.
At 3 months follow up, repeat anti-endomesial antibody was negative suggesting dietary compliance and therefore resolution of her gluten enteropathy. She was now folate (14.6 ug/L) and vitamin B 12 (1727 ng/L) replete. At 6 months, clinic BP was Her vascular endothelial function improved as evidenced by an increase in both basal NO release (assessed using L-NMMA) and stimulated NO release (assessed using ACh) to normal levels. While the response to SNP, an NO-independent direct vasodilator was unaltered. This was associated with a 'cure' of her hypertension. Her initially raised homocysteine level fell to well within the laboratory normal range and interestingly, the response to methionine load was blunted at 15 months indicating improved homocysteine metabolic control. These changes were achieved by dietary manipulation alone.
Discussion
This is an observational rather than a mechanistic study. Although this report on a single patient does not provide conclusive proof that endothelial dysfunction underlies the hypertensive disease process, we believe that in this case, treatment of coeliac disease was associated with reduction in homocysteine levels with parallel 'normalisation' of endothelial function and 'cure' of hypertension. However, this chain of events is only a theoretical possibility. This patient was 'kick-started' with vitamin supplementations for the first 3 months as she commenced treatment with gluten-free diet. It is likely that resumption of normal gastrointestinal absorption allowed her to replenish her stocks of co-factors necessary for normal vascular endothelial function. Importantly, this patient was not obese at baseline hence her hypertension was not weight related. Similarly, gluten-free food products are not low in salt content thus the changes that we observed were unlikely to be related to reduced salt intake although we did not formally measure salt intake.
It is well known that experimental hyperhomocysteinaemia in man causes endothelial dysfunction with increased vascular resistance via an oxidative stress process that reduces NO bioavailability. 15 It is now realised that even moderate elevations in homocysteine levels (Ͼ10 umol/L) are associated with hypertension 16 and death from coronary artery disease. 17 In a report by Nygard and colleagues 17 who followed up 587 patients with coronary artery disease over a median period of 4.6 years, subjects with a homocysteine level Ͼ15 mol/L had a death rate 6.5 times that of those with a homocysteine level Ͻ10 umol/L. Our patient's fasting homocysteine level was thus moderately elevated at baseline but fell by 44% to within normal ranges at 15 months' follow-up when her coeliac disease was treated with diet alone, having stopped her vitamin supplementations for 1 year previously. More recently, there is evidence to suggest that a reduction in a folate-derived co-factor tetrahydrobiopterin causes 'uncoupling' of NO synthase leading to paradoxical NO synthase-mediated formation of superoxide anions and hydrogen peroxide. 18 These reactive agents are detrimental to endothelial function. Hence supplementation with folate alone could to some extent improve endothelial function independently of homocysteine lowering. 19 However in this case, the serum folate at baseline and at 15 months were not different suggesting that other cofactors essential for homocysteine metabolism that we did not measure might be more important.
Two important implications from this unique case study can be drawn. Firstly, this patient had subclinical coeliac disease, in that, apart from a vague sense of tiredness, she was asymptomatic. She had no history of weight loss or altered bowel habits. Hence, under normal clinical circumstances, coeliac disease would not feature as a probable diagnosis.
Notably, she has a daughter with neural tube defect, well known to be associated with folate deficiency. 20 It is conceivable that her folate requirements increased during her pregnancy, and this demand was not met due to malabsorption secondary to her sub-clinical coeliac disease.
Coeliac disease was previously thought to be relatively rare. However, since the diagnosis can now be more easily made by detecting endomesial antibody, a much higher prevalence of about one in 200 in the general population has been uncovered. 21 In view of this, we can speculate that there may be many more patients with hypertension secondary to coeliac disease who have a potentially reversible form of hypertension. Indeed, it may be sensible to look out for this disorder in hypertensive patients with low or normal body mass index.
The second implication of this report is that human hypertension can potentially be directly caused by endothelial dysfunction per se, a finding that has been confirmed in animals. Whether the converse is also true is similarly controversial. There is in vitro experimental data to show that endothelial function in gluteal resistance vessels is affected by increased intravascular pressure. 22 In clinical studies however, BP-lowering with drug treatment is not usually associated with an improvement in endothelial function. 23 It should be borne in mind that high BP is not a disease in itself but an expression of the underlying vascular state given that the cardiac function is intact. Hence, avoiding factors that cause endothelial dysfunction can reduce the risk of vascular diseases and the development of future hypertension. Similarly, the management of hypertension should perhaps be extended to include a study of whether adverse 'endothelial' factors are present, reversal of which may help BP control. This is likely to be more effective prior to the onset of structural vascular target-organ damage.
